Pnd96 - Four-Year Resource Use and Costs Associated With Administration and Monitoring of Disease Modifying Drugs in Patients With Multiple Sclerosis

Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States

“…To our knowledge, this is the first study to evaluate realworld costs of treatment with infusion DMTs (OCR, ATZ and NTZ) during the first year of treatment. Our study showed that the real-world costs of treatment of these infusion DMTs (OCR ¼ $80,582, ATZ ¼ $121,053, NTZ ¼ $93,807) for the for the patients who had at least prescribed annual dosing per the product label were greater than the treatment cost usually perceived and documented in literature which is most commonly calculated based on wholesale acquisition cost via redbook and other ancillary costs for administration and monitoring via physician fee schedule [16][17][18] . For example, published treatment costs for OCR based on wholesale acquisition cost ($65,000) and administration and monitoring costs per fee schedules ($313.85) in 2017 was $65,313 19 .…”

“…For example, published treatment costs for OCR based on wholesale acquisition cost ($65,000) and administration and monitoring costs per fee schedules ($313.85) in 2017 was $65,313 19 . In another study (2018), Beckerman et al estimated 4-year cost of administration ($1,582) and monitoring for OCR ($121) via 2018 physician fee schedule as $1,704, for an annual cost of $426; this amount for administration and monitoring coupled with the 2018 WAC for OCR would yield an annual treatment cost of $65,426 6,17 . Similarly, the average annual cost of NTZ in 2018 can be approximated as $81,797: drug cost of $80,561 per the WAC plus annual administration and monitoring costs of $1,236 from Beckerman et al's 4-year estimate of $4,943 6,17 .…”

“…In another study (2018), Beckerman et al estimated 4-year cost of administration ($1,582) and monitoring for OCR ($121) via 2018 physician fee schedule as $1,704, for an annual cost of $426; this amount for administration and monitoring coupled with the 2018 WAC for OCR would yield an annual treatment cost of $65,426 6,17 . Similarly, the average annual cost of NTZ in 2018 can be approximated as $81,797: drug cost of $80,561 per the WAC plus annual administration and monitoring costs of $1,236 from Beckerman et al's 4-year estimate of $4,943 6,17 . Moreover, treatment cost was calculated for infused DMT by using WAC based on redbook and administration/monitoring cost via physician fee schedule by Institute of Clinical and Economic Review (ICER) for evaluation of cost-effectiveness of DMTs (2017) approved for treatment of MS 18 .…”